MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$1,921,000
EPS
-$0.3
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
-85,000* -0
General and administrative
1,936,000 1,754,000* 1,577,000 1,837,000
Total costs and expenses
1,936,000 1,839,000 1,577,000 1,837,000
Gain on sale of assets, net
---110,000
Loss from operations
-1,936,000 -1,839,000* -1,577,000 -1,837,000
Change in fair value of warrant liability
--1,884,250* -3,455,000
Gain on sale of assets
-9,250* --
Other income/(expense), net
15,000 -234,000* 45,000 -63,000
Loss before tax
--179,500 --
Net loss
-1,921,000 -179,500* -1,532,000 -5,245,000
Unrealized gain on securities available-for-sale
---0
Other comprehensive gain, net of tax
---0
Deemed dividend relating to warrant exchange
-309,000* -618,000 -
Comprehensive loss
----5,245,000
Net loss attributable to common shareholders
-1,921,000 129,500 -2,150,000 -
Basic EPS
-0.3 0.022 -0.4 -1.03
Diluted EPS
-0.3 0.022 -0.4 -1.03
Basic Average Shares
6,406,191 5,899,573 5,435,829 5,086,985
Diluted Average Shares
6,406,191 5,899,573 5,435,829 5,086,985
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to common...-$1,921,000 Net loss-$1,921,000 Otherincome/(expense), net$15,000 Loss from operations-$1,936,000 Total costs andexpenses$1,936,000 General andadministrative$1,936,000

Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc. (MTNB)